Elsevier

Experimental Gerontology

Volume 50, February 2014, Pages 95-105
Experimental Gerontology

Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease

https://doi.org/10.1016/j.exger.2013.11.012Get rights and content

Highlights

  • We used a novel progressive rodent model of Parkinson's disease.

  • Ginseng extract prevented loss of dopaminergic neurons in the substantia nigra.

  • Ginseng extract reduced indices of microgliosis, cell stress and apoptosis.

  • Ginseng extract prevented the accumulation of insoluble α-synuclein aggregates.

  • Ginseng extract prevented the development of locomotor deficits.

Abstract

Panax ginseng has been used in traditional Chinese medicine for centuries. Among its various benefits is a pluripotent targeting of the various events involved in neuronal cell death. This includes anti-inflammatory, anti-oxidant, and anti-apoptotic effects. Indeed, ginseng extract and its individual ginsenosides have been demonstrated to influence a number of biochemical markers implicated in Parkinson's disease (PD) pathogenesis. We have reported previously that administration of the ginseng extract, G115, afforded robust neuroprotection in two rodent models of PD. However, these traditional rodent models are acute in nature and do accurately recapitulate the progressive nature of the disease. Chronic exposure to the dietary phytosterol glucoside, β-sitosterol β-d-glucoside (BSSG) triggers the progressive development of neurological deficits, with behavioral and cellular features that closely approximate those observed in PD patients. Clinical signs and histopathology continue to develop for several months following cessation of exposure to the neurotoxic insult. Here, we utilized this model to further characterize the neuroprotective effects of the ginseng extract, G115. Oral administration of this extract significantly reduced dopaminergic cell loss, microgliosis, and accumulation of α-synuclein aggregates. Further, G115 administration fully prevented the development of locomotor deficits, in the form of reduced locomotor activity and coordination. These results suggest that ginseng extract may be a potential neuroprotective therapy for the treatment of PD.

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the progressive loss of dopaminergic nigrostriatal neurons and the resultant depletion of dopamine in the terminal fields of the caudate-putamen. Key features of PD include, though are not limited to, tremor, rigidity and akinesia/bradykinesia. Dopamine replacement therapy in the form of its precursor, levodopa, remains the primary mode of treatment. However, over time, responsiveness to levodopa declines and dyskinesias develop, which may be due, in part, to ongoing cell loss. To date, only symptomatic treatment is available for PD patients, with no effective means of slowing or stopping the progression of the disease.

While several putative neuroprotective compounds have been described in animal studies, no drug has yet been identified that can definitively slow or stop the progression of PD. This may be due to the multi-factorial nature of the disease, which is characterized by a self-perpetuating cascade involving a myriad of deleterious events at various stages, including mitochondrial dysfunction, short-term and long-term oxidative stress, energy crisis, excitotoxicity, neuroinflammation, and protein aggregation. Not only are multiple factors involved, they appear to impinge upon each other to further promote cell death. In addition, PD cases are highly varied and the relative significance of each event in the disease process may vary among individuals. Unfortunately, putative neuroprotective agents often only target one aspect of the disease process. This may help to explain why many neuroprotective candidates have failed in the clinic despite showing promise in preclinical models.

Ginseng is unique, in comparison to other proposed neuroprotective agents, in that it is not one single compound but a collection of various compounds, called ginsenosides. Indeed, there are more than 60 known ginsenosides (Huang and Williams, 1999), each with unique actions. Ginseng has been demonstrated to modulate several putative biochemical markers shown to be important to the initiation and progression of PD. Various reports have shown the beneficial effects of ginseng or its ginsenoside components in the blockade of toxin uptake (Nah et al., 2009, Tsang et al., 1985a, Tsang et al., 1985b), reductions in excitotoxicity (Gu et al., 2009, Kim et al., 2007, Zhang et al., 2012), antioxidant effects (Chen et al., 2003), both through alterations in nitric oxide production as well as antioxidant enzyme activities required to eliminate free radicals, anti-inflammatory actions (Lee et al., 2012a, Lin et al., 2007, Yu and Li, 2000), and altered expression of neurotrophic factors (Liang et al., 2010, Wang et al., 2013). Ginseng has demonstrated neuroprotective capabilities in a variety of paradigms including stroke (He et al., 2012, Lee et al., 2011, Ye et al., 2013), Alzheimer's disease (Fang et al., 2012), Huntington's disease (Wu et al., 2009), ALS (Jiang et al., 2000), and PD (Chen et al., 2005a, Luo et al., 2011, Van Kampen et al., 2003). Indeed, we have previously demonstrated that the ginseng extract, G115, provides protection against the neurotoxic effects of MPTP and its neurotoxic metabolite, MPP+, in rodent models of PD (Van Kampen et al., 2003).

One other reason why neuroprotective candidates do so poorly in the clinic may involve the models used for preclinical screening. The vast majority of PD animal models fail to mimic the progressive nature of the disease, which may be critical for the proper identification of neuroprotective therapies. In order to effectively screen therapies designed to slow or halt disease progression, it may be necessary to replicate such progression. Chronic exposure to dietary phytosterol glucosides has been found to be neurotoxic (Khabazian et al., 2002, Schulz et al., 2006, Tabata et al., 2008, Wilson et al., 2002). When fed to rats, β-sitosterol β-d-glucoside (BSSG) triggers the progressive development of neurological deficits, with behavioral and cellular features that closely approximate those observed in Parkinson's patients. These include motor abnormalities, striatal dopamine loss, loss of dopaminergic neurons of the SNc, and the appearance of Lewy body-like α-synuclein aggregates (Shen et al., 2010, Van Kampen et al., 2013). Clinical signs and histopathology continue to develop for several months following cessation of exposure to the neurotoxic insult.

Here, we examine the neuroprotective effects of the ginseng extract, G115, using this novel progressive rodent model of PD, assessing locomotor function, nigrostriatal cell loss, inflammation, and accumulation of protein aggregates.

Section snippets

Animals

All studies used female Sprague Dawley rats (Charles River), approximately 3 months of age. Animals were housed in a temperature-controlled environment with a 12 h light/dark cycle and 24 hour ad libitum access to standard chow and water, except during staircase step test training, when ad libitum access was limited to 4 h each day. All animal experimentation was conducted in accordance with the CCAC guidelines for the care and use of laboratory animals and was approved by the University of Prince

The ginseng extract, G115, prevents the development of locomotor impairments

Eighteen, twenty six and thirty four weeks following the initiation of BSSG intoxication, animals underwent assessments for locomotor impairments. Locomotor activity was measured for 1 h using a home cage video tracking system (MED Associates Inc.). Using this measure of akinesia/bradykinesia, BSSG was found to have no effect on locomotor function at 18 weeks, when toxin exposure was complete. However, BSSG significantly reduced locomotor activity, as compared to flour-treated controls, at the 26

Discussion

Collectively, these data suggest a possible role for ginseng extract as a neuroprotective therapy for PD. Here, we have demonstrated its ability to prevent BSSG-induced apoptosis and loss of SNc dopaminergic neurons, a key characteristic feature of PD pathology. This preservation of nigral neurons was reflected by the relative absence of locomotor abnormalities, as open field assessments revealed no reductions in locomotor activity. Fine motor control in the skilled reaching task was also

Conclusions

The ginseng extract, G115, provided near-complete protection against dopaminergic cell loss in the BSSG model of PD. This was accompanied by a reduction in indices of inflammation, apoptosis and cell stress. Further, locomotor deficits, characteristic of this and many other models of PD, failed to develop in those animals treated with G115. These data suggest that ginseng extract may be an effective neuroprotective therapy for the treatment of PD and may represent a safe means of early

Conflict of interest

Dr.s Van Kampen, Baranowski, and Kay were employed by Neurodyn Inc.

Acknowledgments

This work was supported, in part, by the Atlantic Canada Opportunities Agency. Special thanks to Dr. Harold Robertson for his assistance in reviewing this work.

References (70)

  • A.S. Lee

    The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress

    Methods

    (2005)
  • W. Liang et al.

    Ginsenosides Rb1 and Rg1 promote proliferation and expression of neurotrophic factors in primary Schwann cell cultures

    Brain Res.

    (2010)
  • F.C. Luo et al.

    Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo

    J. Ethnopharmacol.

    (2011)
  • S.Y. Nah et al.

    Effects of ginseng saponin on acute cocaine-induced alterations in evoked dopamine release and uptake in the rat brain nucleus accumbens

    Brain Res.

    (2009)
  • S. Paul et al.

    Inhibition of inflammations and macrophage activation by ginsenoside-Re isolated from Korean ginseng (Panax ginseng C.A. Meyer). Food and Chemical

    Toxicology

    (2012)
  • J.D. Schulz et al.

    Cycad toxins, Helicobacter pylori and parkinsonism: cholesterol glucosides as the common denomenator

    Med. Hypotheses

    (2006)
  • J.M. Van Kampen et al.

    Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease

    Exp. Neurol.

    (2003)
  • Y. Yoshimoto et al.

    Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease

    Brain Res.

    (1995)
  • M.B.H. Youdim et al.

    Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

    Trends Pharmacol. Sci.

    (2005)
  • R.D. Abbott et al.

    Excessive daytime sleepiness and subsequent development of Parkinson disease

    Neurology

    (2005)
  • C.H. Adler

    Premotor symptoms and early diagnosis of Parkinson's disease

    Int. J. Neurosci.

    (2011)
  • X.C. Chen et al.

    Ginsenosdie Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress

    Yao Xue Xue Bao

    (2005)
  • X.C. Chen et al.

    Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress

    Yao Xue Xue Bao

    (2005)
  • I.H. Cho

    Effects of Panax ginseng in neurodegenerative diseases

    J. Ginseng Res.

    (2012)
  • J.T. Coon et al.

    Panax ginseng: a systematic review of adverse effects and drug interactions

    Drug Saf.

    (2002)
  • A. Currais et al.

    Functional consequences of age-dependent changes in glutathione status in the brain

    Antioxid. Redox Signal.

    (2013)
  • D.M. Frim et al.

    Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpridinium toxicity to dopaminergic neurons in the rat

    Proc. Natl. Acad. Sci. U. S. A.

    (1994)
  • X. Gao et al.

    A prospective study of bowel movement frequency and risk of Parkinson's disease

    Am. J. Epidemiol.

    (2011)
  • B. Gu et al.

    Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-d-aspartate receptors composed of an NR1/NR2B subunit assembly

    J. Neurosci. Res.

    (2009)
  • K.C. Huang et al.

    The Pharmacology of Chinese Herbs

    (1999)
  • L. Ishihar et al.

    A systematic review of depression and mental illness preceding Parkinson's disease

    Acta Neurol. Scand.

    (2006)
  • B. Jiang et al.

    Antidepressant-like effects of ginsenoside Rg1 are due to activation of the BDNF signalling pathway and neurogenesis in the hippocampus

    Br. J. Pharmacol.

    (2012)
  • R.J. Kaufman

    Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls

    Genes Dev.

    (1999)
  • I. Khabazian et al.

    Isolation of various forms fo sterol beta-d-glucoside from the seed of Cycas circinalis: neurotoxicity and implications for ALS-parkinsonism dementia complex

    J. Neurochem.

    (2002)
  • P.Y. Lam et al.

    Elevated neuronal nitric oxide synthase expression during ageing and mitochondrial energy production

    Free Radic. Res.

    (2009)
  • Cited by (72)

    • The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine

      2022, Phytomedicine
      Citation Excerpt :

      Ginseng Radix et Rhizoma (GRR) is the best-characterized Chinese medicine of strengthening the spleen having been confirmed to produce a variety of therapeutic effects in PD. In multiple animal models of PD, GRR has been shown to alleviate behavioral dysfunction, prevent the loss of TH-positive neurons and the increase of TUNEL-positive cells, and suppress the cleavage of p35 to p25 and activation of caspase-3 (Van Kampen et al., 2003;Jun et al., 2015; Van Kampen et al., 2014). In addition, the water extract of GRR significantly promoted the increase rate of cell viability and the reduce proportion of apoptotic cells, prevent the morphological deterioration of cells and DNA fragmentation, and reduced the ratio of Bax/Bcl-2 and the levels of cleaved caspase-3 and cytochrome C in MPP+-induced SH-SY5Y cells (Hu et al., 2011).

    • Ginsenosides attenuate bioenergetics and morphology of mitochondria in cultured PC12 cells under the insult of amyloid beta-peptide

      2021, Journal of Ginseng Research
      Citation Excerpt :

      In aged mouse model, oral administration of Rg1 up-regulated the protein expression of brain-derived neurotrophic factor via activation of protein kinase A and cyclic adenosine monophosphate-response element-binding protein (CREB) phosphorylation in the brain, and thereafter the memory loss in aged mouse could be recovered [40]. In the β-sitosterol β-D-glucoside-induced Parkinson animal model, the oral administration of ginseng extract could reduce the protein expression of α-synuclein in the striatum, and which prevented the loss of dopaminergic neuron in substantia nigra [41]. Therefore, these lines of evidence strongly support the possible application of ginsenoside in treating degenerative brain disease.

    • Non-polyphenolic natural inhibitors of amyloid aggregation

      2020, European Journal of Medicinal Chemistry
    View all citing articles on Scopus
    View full text